A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI By Ogkologos - January 16, 2026 369 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SACHI study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid... August 12, 2025 The Grace Project Helps Breast Cancer Survivors Practice Body Acceptance and... July 27, 2021 Great Oaks Grow From Small Acorns Oncology Is Committed to Doing... September 9, 2022 New Research in Treating Lymphoma and Improving Equity in Cancer Clinical... February 3, 2022 Load more HOT NEWS What to Know About Navigating Cancer Care With a Disability: An... Survey results reveal attitudes towards cancer screening during the pandemic ‘Levelling Up’: What should it mean for cancer? Lisocabtagene Maraleucel in Relapsed or Refractory Large B-cell Lymphomas
